Distinct brain responses to psilocybin and escitalopram in depression captured by the Fluctuation-Dissipation Theorem

A new study shows that psilocybin, the active compound in magic mushrooms, and escitalopram, a common antidepressant, change the brain in opposite ways — and these differences might explain why one treatment feels more powerful than the other for some people.

Bottom line: A new study suggests that psilocybin and escitalopram alter the brain’s hierarchical organization in fundamentally different ways, and that these changes — measured using a concept from statistical mechanics — could help predict which treatment might work best for a given patient.

How Psilocybin and Antidepressants Rewire the Brain — and Why It Matters

The brain is never still. It pulses with electrical signals, and its networks reconfigure constantly. But what happens when a drug like psilocybin or escitalopram steps in and changes that?

In a recent preprint study, researchers used a new approach to map these changes. They looked at the brain’s “hierarchical organization” — how different regions work together in a structured, layered way, like the layers of a cake. This structure is important for normal brain function, but it can be disrupted in depression, where communication between brain regions breaks down.

Using resting-state fMRI — a technique that captures brain activity when it’s not doing anything specific — the team built whole-brain models for each participant. Then, they measured how these models changed before and after treatment with either psilocybin or escitalopram. The key tool? The Fluctuation-Dissipation Theorem (FDT), a concept from statistical mechanics that describes how systems move away from equilibrium.

In simple terms, FDT helps scientists measure how far a system — like the brain — is from a state of balance. If the brain is operating far from equilibrium, it means its activity is more dynamic, chaotic, or unpredictable. And that’s exactly what the researchers found: psilocybin and escitalopram caused opposite shifts in the brain’s non-equilibrium dynamics.

Psilocybin pushed the brain toward a more chaotic, less structured state — a flattening of its hierarchical organization. Escitalopram, on the other hand, stabilized the brain, bringing it closer to equilibrium. These results aren’t just academic. They hint at why some people respond better to one treatment than the other — and maybe even suggest new ways to personalize depression care.

The Brain’s “Flattening” and the Paradox of Psychedelics

The idea that psychedelics flatten the brain’s hierarchy isn’t new. A related study earlier this year found that psilocybin, LSD, and DMT all caused a similar effect. But what makes this finding strange is the paradox it reveals.

When the brain is in a state of reduced consciousness — like during deep sleep or under anesthesia — its hierarchy also flattens. But with psychedelics, this flattening occurs even as the brain becomes more complex. That seems contradictory: how can a system become both simpler and more complex at the same time?

The answer lies in the concept of statistical mechanics. The researchers redefined hierarchy not just as a static structure but as a measure of how close the brain is to thermodynamic equilibrium. In other words, they looked at the brain not just as a machine, but as a system that fluctuates between order and chaos — and that’s where the magic happens.

When psilocybin is introduced, the brain moves toward equilibrium, but in a way that increases the complexity of its activity. This is different from the brain’s natural state during unconsciousness, where complexity drops. The result is a kind of “paradoxical flattening” — a state that is simultaneously simpler and more intricate. This might explain why people often report feeling both relaxed and intensely aware during a psychedelic experience.

Why This Matters for Understanding Depression and Treatment

Depression is more than just feeling sad. It’s a disruption of the brain’s ability to regulate emotions, think clearly, and engage with the world. And if the brain’s hierarchical organization is key to these functions, then any treatment that alters that structure could be a game-changer.

The study found that baseline measures — like how the brain was structured before treatment — could predict who would respond to psilocybin or escitalopram. That’s a big deal. It suggests that the brain’s pre-existing state might be a better indicator of treatment success than the drug itself. If that’s true, it could lead to more personalized approaches to treating depression.

But the implications go deeper. The Fluctuation-Dissipation Theorem, a tool originally used in physics, is now being applied to the brain. This isn’t just a curiosity — it’s a sign that we’re starting to see the brain not as a collection of discrete parts, but as a system governed by the same principles that shape everything from weather patterns to the flow of electricity.

Frequently Asked Questions

Q: Does this mean psilocybin is a better antidepressant than escitalopram?
A: Not necessarily. The study shows that the two drugs alter the brain’s hierarchical organization in different ways, but it doesn’t compare their overall effectiveness. The focus is on understanding the mechanisms, not making a case for one drug over the other.

Q: How can the Fluctuation-Dissipation Theorem apply to the brain?
A: FDT is a concept from statistical mechanics that describes how systems move away from equilibrium. The researchers used it to measure how far the brain’s activity deviates from a stable state, which could help identify how different treatments affect brain dynamics.

Q: Can this approach be used for other mental health conditions?
A: The researchers suggest it could. The study’s focus on hierarchical reconfiguration and non-equilibrium dynamics might be applicable to conditions like anxiety, PTSD, or even schizophrenia — all of which involve disrupted brain networks.

Q: What’s the next step for this research?
A: The team is planning to expand the study to include more participants and explore how these brain changes correlate with symptom improvement. They’re also looking into how other drugs or interventions might affect the same metrics.

Sources

• ¶Distinct brain responses to psilocybin and escitalopram in depression captured by the Fluctuation-Dissipation Theorem (bioRxiv, 2026)
• ¶Brain dynamics of classical psychedelics show paradoxical hierarchical flattening with increased complexity (bioRxiv, 2024)
• ¶Evolution’s boldest trick: Neurotransmission modulated whole-brain computation captures full task repertoire (bioRxiv, 2025)

Educational Disclaimer

This article is for informational and educational purposes only. It is not medical advice, mental health advice, diagnosis, treatment guidance, or a recommendation to use any substance, supplement, therapy, or protocol.

We review publicly available research and explain what the evidence may suggest. Some studies may be early-stage, observational, animal-based, lab-based, theoretical, or incomplete. Always consult a qualified professional before making health-related decisions.

If you or someone you know is struggling, you are not alone. In the US, call or text 988 (Suicide & Crisis Lifeline). Elsewhere, contact your local emergency or crisis service.

Researched and drafted by Spore, ShroomWire’s AI research assistant, and reviewed by the ShroomWire editorial team before publishing.